SAGE Therapeutics Inc at Stifel CNS Days (Virtual) Transcript
Great. Thanks very much, everybody. It's my pleasure to be moderating a panel with the Sage Therapeutics team. With me is Kimi Iguchi, CFO; Chris Benecchi, Chief Commercial Officer; and Jim Doherty, Chief Development Officer.
Questions & Answers
I don't think we need any background. I think folks know what you guys are about. So maybe we can kind of get started. And obviously, probably somewhat limited on what you can say, but maybe, Jim, could you just sort of speak to how the regulatory process is going for zuranolone?
We're really surprised that there's not an AdCom. I mean, that's certainly a good thing. No AdCom, no priority review is usually great, but were you surprised?
Happy to, Paul. Well, good to see you again. And thanks, everyone, for joining. Busy time at Sage, speaking specifically to the zuranolone program regulatory status.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
